Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amphotericin B: an introduction.

D W Warnock1

  • 1Department of Microbiology, Bristol Royal Infirmary, UK.

The Journal of Antimicrobial Chemotherapy
|October 1, 1991
PubMed
Summary
This summary is machine-generated.

Amphotericin B targets fungal cell membranes, but resistance can occur. Drug combinations show potential but require further clinical trials for efficacy in treating fungal infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Journal of clinical microbiology·2006
Same author

Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program.

Medical mycology·2005
Same author

Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.

Journal of clinical microbiology·2004
Same author

Epidemiology, clinical manifestations, and therapy of infections caused by dematiaceous fungi.

Journal of chemotherapy (Florence, Italy)·2004
Same author

Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2002
Same author

Coccidioidomycosis in India: report of a second imported case.

Medical mycology·2002
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Amphotericin B is a broad-spectrum antifungal agent effective against major human fungal pathogens.
  • It functions by binding to fungal cell membrane sterols, disrupting barrier integrity and leading to cell death.

Purpose of the Study:

  • To review the mechanism of action, resistance patterns, and drug interactions of Amphotericin B.
  • To assess the current evidence for combination antifungal therapies.

Main Methods:

  • Literature review of Amphotericin B's mechanism, resistance, and interactions.
  • Analysis of in vitro and in vivo studies on drug combinations.

Main Results:

  • Fungal resistance to Amphotericin B is often linked to alterations in membrane sterol composition, particularly in Candida albicans and Cryptococcus neoformans.

Related Experiment Videos

  • Treatment failure with Amphotericin B is uncommon but may occur in patients on cytotoxic drugs.
  • Drug interactions have been observed, but controlled trials supporting combination therapy are limited, except for a report on Amphotericin B and flucytosine for cryptococcal meningitis.

    • Conclusions:

    • Amphotericin B remains a crucial antifungal, but understanding resistance mechanisms is important.
    • Further controlled clinical trials are needed to validate the use of combination antifungal therapies in human infections.